These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 11793841)

  • 21. Tegumentary leishmaniasis as a manifestation of immune reconstitution inflammatory syndrome in 2 patients with AIDS.
    Posada-Vergara MP; Lindoso JA; Tolezano JE; Pereira-Chioccola VL; Silva MV; Goto H
    J Infect Dis; 2005 Nov; 192(10):1819-22. PubMed ID: 16235183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Kaposi sarcoma: a case of immune reconstitution inflammatory syndrome.
    Papagatsia Z; Jones J; Morgan P; Tappuni AR
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2009 Jul; 108(1):70-5. PubMed ID: 19464210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trends in opportunistic infections in the pre- and post-highly active antiretroviral therapy eras among HIV-infected children in the Perinatal AIDS Collaborative Transmission Study, 1986-2004.
    Nesheim SR; Kapogiannis BG; Soe MM; Sullivan KM; Abrams E; Farley J; Palumbo P; Koenig LJ; Bulterys M
    Pediatrics; 2007 Jul; 120(1):100-9. PubMed ID: 17606567
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Leprosy and immune reconstitution syndrome in AIDS].
    Aubry P; Bobin P
    Bull Soc Pathol Exot; 2008 Feb; 101(1):58-9. PubMed ID: 18432011
    [TBL] [Abstract][Full Text] [Related]  

  • 25. AIDS-associated cryptococcosis: a comparison of epidemiology, clinical features and outcome in the pre- and post-HAART eras. Experience of a single centre in Italy.
    Antinori S; Ridolfo A; Fasan M; Magni C; Galimberti L; Milazzo L; Sollima S; Adorni F; Giuliani G; Galli M; Corbellino M; Parravicini C
    HIV Med; 2009 Jan; 10(1):6-11. PubMed ID: 19125961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Increased incidence of mucosal candidiasis after HAART initiation: a benign form of immune reconstitution disease?
    Nacher M; Vantilcke V; Huber F; Mahamat A; El Guedj M; Randrianjohany A; Clyti E; Aznar C; Carme B; Couppié P
    AIDS; 2007 Nov; 21(18):2534-6. PubMed ID: 18025892
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immune reconstitution inflammatory syndrome (IRIS) due to Bacille Calmette Guerin (BCG) in an HIV-positive child.
    Kroidl A; Huck K; Weinspach S; Gudowius S; Mackenzie CR; Oette M; Häussinger D; Niehues T
    Scand J Infect Dis; 2006; 38(8):716-8. PubMed ID: 16857624
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune reconstitution inflammatory syndrome-Unmasking endophthalmic, lymphadenopathic, and neuromeningeal cryptococcosis in an HIV-infected patient starting highly active antiretroviral therapy.
    Martinez-Zapico A; Asensi V; Fuentes N; Fonollá M; Rodriguez M; Cárcaba V; Carton JA
    AIDS Res Hum Retroviruses; 2014 May; 30(5):434-5. PubMed ID: 24724818
    [No Abstract]   [Full Text] [Related]  

  • 29. Immune reconstitution diseases: is it possible to establish recommendations?
    Knysz B; Gładysz A
    Postepy Hig Med Dosw (Online); 2007; 61():220-5. PubMed ID: 17507869
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Concurrent granulomatous Pneumocystis carinii and Mycobacterium xenopi pneumonia: an unusual manifestation of HIV immune reconstitution disease.
    Chen F; Sethi G; Goldin R; Wright AR; Lacey CJ
    Thorax; 2004 Nov; 59(11):997-9. PubMed ID: 15516479
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of hepatitis C infection on progression of HIV disease and early response to initial antiretroviral therapy.
    Sullivan PS; Hanson DL; Teshale EH; Wotring LL; Brooks JT
    AIDS; 2006 May; 20(8):1171-9. PubMed ID: 16691069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immune restoration disease in HIV-infected individuals receiving highly active antiretroviral therapy: clinical and immunological characteristics.
    de Boer MG; Kroon FP; Kauffmann RH; Vriesendorp R; Zwinderman K; van Dissel JT
    Neth J Med; 2003 Dec; 61(12):408-12. PubMed ID: 15025416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship of in vivo and ex vivo levels of TH1 and TH2 cytokines with viremia in HAART patients with and without opportunistic infections.
    Sindhu S; Toma E; Cordeiro P; Ahmad R; Morisset R; Menezes J
    J Med Virol; 2006 Apr; 78(4):431-9. PubMed ID: 16482539
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reactivation of retinal toxoplasmosis despite evidence of immune response to highly active antiretroviral therapy.
    Stout JE; Lai JC; Giner J; Hamilton CD
    Clin Infect Dis; 2002 Aug; 35(4):e37-9. PubMed ID: 12145740
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Kaposi's sarcoma-associated herpesvirus-specific immune reconstitution and antiviral effect of combined HAART/chemotherapy in HIV clade C-infected individuals with Kaposi's sarcoma.
    Bihl F; Mosam A; Henry LN; Chisholm JV; Dollard S; Gumbi P; Cassol E; Page T; Mueller N; Kiepiela P; Martin JN; Coovadia HM; Scadden DT; Brander C
    AIDS; 2007 Jun; 21(10):1245-52. PubMed ID: 17545700
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune restoration and HAART: new clinical and in vitro data.
    Laurence J
    AIDS Read; 2002 Oct; 12(10):421-2. PubMed ID: 12405097
    [No Abstract]   [Full Text] [Related]  

  • 37. [Case of highly active anti-retroviral therapy-induced immune reconstitution inflammatory syndrome in AIDS-related progressive multifocal leukoencephalopathy].
    Imamura E; Yamashita H; Fukuhara T; Sawa H; Nagashima K; Kuwabara M; Tokinobu H
    Rinsho Shinkeigaku; 2007 Oct; 47(10):650-6. PubMed ID: 18095498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mediastinitis due to cryptococcal infection: a new clinical entity in the HAART era.
    Trevenzoli M; Cattelan AM; Rea F; Sasset L; Semisa M; Lanzafame M; Meneghetti F; Cadrobbi P
    J Infect; 2002 Oct; 45(3):173-9. PubMed ID: 12387774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Initiation of highly active antiretroviral therapy in advanced AIDS with CD4 < 50 cells/mm3 in a resource-limited setting: efficacy and tolerability.
    Sungkanuparph S; Kiertiburanakul S; Manosuthi W; Kiatatchasai W; Vibhagool A
    Int J STD AIDS; 2005 Mar; 16(3):243-6. PubMed ID: 15829026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. When to initiate highly active antiretroviral therapy in low-resource settings: the Moroccan experience.
    Loubiere S; el Filal KM; Sodqi M; Loundou A; Luchini S; Cleary S; Moatti JP; Himmich H
    Antivir Ther; 2008; 13(2):241-51. PubMed ID: 18505175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.